Quotient Sciences Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form

With trusted scientific insight brought to every program, Quotient Sciences is a drug development & manufacturing accelerator with a mission to help our partners bring molecules to cures, fast. We pioneered the integration of CRO/CDMO solutions with Translational Pharmaceutics®—a disruptive platform to enable greater efficiency in drug development. This comprehensive approach to formulation development, on-demand GMP drug product manufacturing & clinical testing leverages actionable data for more successful outcomes, reducing overall development timelines by 9–12 months on average.

Accelerated pathways from global agencies like the FDA, MHRA, and EMA help meet unmet medical needs and improve treatments. Yet, compressed timelines pose challenges, ranging from limited API supply to clinical trial logistics. In Quotient Sciences' presentation, we explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.